Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is expected to report third quarter earnings results, after market close, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.6 per share from revenue of $ 0.42 million.
Looking ahead, the full year loss are expected at $ 2.81 per share on the revenues of $ 3.16 million.
Stock Performance
On Friday, shares of Marinus Pharmaceuticals, Inc. has traded high as $ 14.02 and has cracked $ 13.33 on the downward trend, reaching $ 13.42 with volume of 283.90 thousand shares.
According to the previous trading day, closing price of $ 13.42, representing a 234.16 % increase from the 52 week low of $ 4.04 and a 17.08 % decrease over the 52 week high of $ 16.28.
The company has a market capital of $ 410.28 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 28th September 2020, maintained by HC Wainwright at Buy rating, with $ 35.00 target price.
- On 15th September 2020, maintained by SVB Leerink at Outperform rating, with $ 8.00 target price.
Conference Call
Marinus Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.marinuspharma.com
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The companys ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors.
